Literature DB >> 8891069

Dystrophin-associated protein abnormalities in dystrophin-deficient muscle fibers from symptomatic and asymptomatic Duchenne/Becker muscular dystrophy carriers.

C Di Blasi1, L Morandi, R Barresi, F Blasevich, F Cornelio, M Mora.   

Abstract

The absence of dystrophin in muscle fibers is associated with a major reduction in dystrophin-associated proteins (DAPs) and disruption of the linkage between the subsarcolemmal cytoskeleton and the extracellular matrix. We investigated the expression of the DAPs beta-dystroglycan, alpha-sarcoglycan, gamma-sarcoglycan and syntrophin as well as utrophin in the muscles of 13 Duchenne muscular dystrophy (DMD) carriers (with variable percentages of dystrophin-deficient fibers and with a range of clinical symptoms), 2 Becker muscular dystrophy (BMD) carriers (expressing a highly truncated protein in some fibers), 2 girls with a DMD-like phenotype, and 11 BMD carriers with almost normal dystrophin expression (reduced or patchy distribution in a few fibers only and rare dystrophin-deficient fibers). DAPs were highly reduced in all fibers lacking dystrophin in the DMD carriers, but were almost normal in the dystrophin-deficient fibers of the 2 BMD carriers with highly truncated dystrophin. In the 11 BMD carriers with nearly normal dystrophin, the few fibers with reduced or patchy dystrophin immunostaining also showed reduced DAP expression in correlation with dystrophin expression. Immunoblot for beta-dystroglycan and alpha-sarcoglycan confirmed the immunohistochemical findings. Utrophin expression was slightly increased in a proportion of fibers in the DMD and BMD carriers with dystrophin mosaicism. We found no correlation between utrophin expression and DAP expression. We conclude that absence or reduction of dystrophin in muscle fibers of DMD and BMD carriers causes a reduction of DAPs in the same fibers, as observed in DMD and BMD patients, while utrophin does not seem to play a role in DAP expression in adult muscle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891069     DOI: 10.1007/s004010050532

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  8 in total

1.  The GTPase RhoA increases utrophin expression and stability, as well as its localization at the plasma membrane.

Authors:  Armelle Bonet-Kerrache; Mathieu Fortier; Franck Comunale; Cécile Gauthier-Rouvière
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

2.  Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Authors:  Sarah Forrest; Penny L Meloni; Francesco Muntoni; Jihee Kim; Sue Fletcher; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

3.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Authors:  Annemieke Aartsma-Rus; Anneke A M Janson; Wendy E Kaman; Mattie Bremmer-Bout; Gert-Jan B van Ommen; Johan T den Dunnen; Judith C T van Deutekom
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

4.  Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle.

Authors:  Erik P Rader; Rolf Turk; Tobias Willer; Daniel Beltrán; Kei-Ichiro Inamori; Taylor A Peterson; Jeffrey Engle; Sally Prouty; Kiichiro Matsumura; Fumiaki Saito; Mary E Anderson; Kevin P Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-13       Impact factor: 11.205

5.  Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model.

Authors:  Gerard A Marchal; Maaike van Putten; Arie O Verkerk; Simona Casini; Kayleigh Putker; Shirley C M van Amersfoorth; Annemieke Aartsma-Rus; Elisabeth M Lodder; Carol Ann Remme
Journal:  Sci Rep       Date:  2021-05-07       Impact factor: 4.379

Review 6.  Muscular dystrophy: Experimental animal models and therapeutic approaches (Review).

Authors:  Gisela Gaina; Alexandra Popa Gruianu
Journal:  Exp Ther Med       Date:  2021-04-14       Impact factor: 2.447

Review 7.  Genetic Engineering of Dystroglycan in Animal Models of Muscular Dystrophy.

Authors:  Francesca Sciandra; Maria Giulia Bigotti; Bruno Giardina; Manuela Bozzi; Andrea Brancaccio
Journal:  Biomed Res Int       Date:  2015-08-24       Impact factor: 3.411

8.  Development of rabbit monoclonal antibodies for detection of alpha-dystroglycan in normal and dystrophic tissue.

Authors:  Marisa J Fortunato; Charlotte E Ball; Katrin Hollinger; Niraj B Patel; Jill N Modi; Vedika Rajasekaran; Dan J Nonneman; Jason W Ross; Eileen J Kennedy; Joshua T Selsby; Aaron M Beedle
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.